RMD · News · 20260806N

Revenue Performance and Mix

RESMED INC · 2026-08-06 · Importance 36 · Surprise 40 · No source text

ResMed's fourth-quarter fiscal 2026 revenue increased 9% year over year to a record $1.5 billion, or 8% on a constant-currency basis. Fiscal 2026 revenue increased 10% to $5.653 billion. Growth reflected continued expansion across global sleep and breathing health and residential care software, while Astral ventilator sales were affected by a field safety action. The company reported fourth-quarter GAAP diluted EPS of $2.64, up 2% year over year, and non-GAAP diluted EPS of $2.95, up 16%.

Key facts

• Fiscal year 2026 revenue increased 10% to $5,653 million (reported as $5,653M / $5.65 billion). source
• Q4 revenue increased by 9% to a record $1.5 billion. source
• ResMed reported exceeding Q4 adjusted EPS estimates: $2.95 reported vs. $2.90 consensus (and vs. FactSet est of $2.89 in another report). source
• Non-GAAP diluted EPS for FY2026 rose 17% to $11.17. source
• Q4 GAAP diluted earnings per share was $2.64. source

Impact estimates